Novamind (NM: CSE) Is Building the Infrastructure Required for a Regulated Psychedelics Industry

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to 2027.

As a consequence of the increasing incidence of mental health disorders, global demand for mental health facilities is increasing.

Psychedelics are going to go through parabolic, paradigm-shifting growth because of their ability to treat anxiety and depression amongst other things

Novamind is a leading mental health company specialized in psychedelic medicine, building the infrastructure required for a regulated psychedelics industry.

Highlights:

• Rapidly expanding a network of outpatient mental health clinics and research sites
• 4 clinics in Utah, 1 more anticipated this quarter
• Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
  Ketamine treatment volume grew 90% from 2019 to 2020
  During the same period, total Spravato™ treatments rose 400%
• Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
• Building centers of excellence for future approved psychedelic treatments
• Approximately CAN$1,900,000 in 2019 revenue
• Strong insider ownership (32.3%)